The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Open accessAbstract
Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis. Here we describe the profile of ON01910, a small molecule inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. This compound was not ATP-competitive, but competed for the substrate binding site of the enzyme. In vivo, this compound did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models. ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Cited by
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Arkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Twarog, N. R., Low, J. A., Currier, D. G., Miller, G., Chen, T., & Shelat, A. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149439 · Cited by 16
Metadata
- Authors
- Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 7
- Issue
- 3
- Pages
- 275-286
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1976023782
- Cited by
- 367
- References
- 1
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. https://app.cochat.ai/papers/10.1016/j.ccr.2005.02.009
- The paper
- Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. https://doi.org/10.1016/j.ccr.2005.02.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.